Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy


Friday, July 19, 2019

Saturday, July 20, 2019

Sunday, July 21, 2019

Monday, July 22, 2019

Friday, July 19

Welcome and Opening Keynote Addresses

5-7 p.m.

Next generation CAR T cells
Crystal L. Mackall, Stanford University, Stanford, California

A path towards successful T cell therapy for solid cancers
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Opening Reception
7-9 p.m.

Top of page

Saturday, July 20

Continental Breakfast
7-8 a.m.

Plenary Session 1: Cellular Therapy Clinical Updates I
Session Chair: Christine E. Brown, City of Hope National Medical Center, Duarte, California
8-10 a.m.

Chimeric antigen receptor T cell therapy for chronic lymphocytic leukemia
Saar I. Gill, University of Pennsylvania, Philadelphia, Pennsylvania

CAR-T antigen evasion: The emerging role for multi-targeted CAR therapy
David B. Miklos, Stanford University, Stanford, California

Advancing CAR T cell therapy for treatment of brain tumors
Christine E. Brown

Targeting pancreatic cancer using nonengineered, multiantigen-specific T cells (TACTOPS)*
Brandon G. Smaglo, Baylor College of Medicine, Houston, Texas

Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)*
Anna Nowak, Immatics Biotechnologies GmbH, Tübingen, Germany

10-10:30 a.m.

Plenary Session 2: CAR T Cell Engineering – Barriers for Targeting Solid Tumors
Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington

10:30 a.m.-12:30 p.m.

Engineering lymphocytes for the adoptive immunotherapy of solid tumors
Stephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, Tennessee

Molecular and epigenetic programs defining tumor-specific T cell dysfunction and therapeutic reprogrammability
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

Engineering T cells to eradicate tumors: It starts with the TCR but doesn't stop there
Philip D. Greenberg

HER2-specific chimeric antigen receptor T cells with NKILA knockout improves therapeutic effects towards HER2+ breast cancer*
Erwei Song, Sun Yat-sen University, Guangzhou, China

Regulation of CD40L on chimeric antigen receptor T cells enhances immune function translating to antitumor effects* Michelle Fleury, Obsidian Therapeutics, Cambridge, Massachusetts

Poster Session A / Lunch
12:30-2:30 p.m.

Plenary Session 3: Scalability of T Cell Therapy – Driving Down Costs
Session Chair: Barbra J. Sasu, Allogene Therapeutics, San Francisco, California
2:30-4 p.m.

Allogene: Leading the next revolution in cell therapy
Barbra J. Sasu

Scalability of T cell therapy
Gwendolyn Binder-Scholl, Cabaletta Bio, Philadelphia, Pennsylvania

Innovating and planning our way to improve affordability and accessibility for chimeric antigen receptor (CAR) T cell therapies
Heidi Zhang, Celgene Corporation, Seattle, Washington

4-4:30 p.m.

Plenary Session 4: NK and Other Immune Cell Therapies
Session Chair: Catherine M. Bollard, Children’s National Health System, Washington, D.C.
4:30-6:30 p.m.

Off-the-shelf CAR-engineered cord blood-derived NK cells for the treatment of cancer
Katy Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas

TGFβ-resistant T and NK cells for cancer
Catherine M. Bollard

Selective expansion of adaptive natural killer cells for cancer immunotherapy
Karl Johan Malmberg, The University of Oslo, Oslo, Norway

ACTR and BOXR T-cell therapies: Addressing the challenges of solid tumors*
Heather Huet, Unum Therapeutics, Cambridge, Massachusetts

Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies*
Marissa Del Real, City of Hope, Duarte, California

Top of page

Sunday, July 21

Continental Breakfast
7-8 a.m.

Plenary Session 5: Cellular Therapy Clinical Updates II
Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-10 a.m.

CAR T-cell therapy for lymphomas: Current and future strategies
Sattva S. Neelapu

Expanding CAR T cell therapy to a wide spectrum of pediatric malignancies
Julie R. Park, Seattle Children's Hospital, Seattle, Washington

Addressing relapse associated with leukemic resistance to CAR T cells
Terry J. Fry, University of Colorado Denver and Children's Hospital Colorado, Aurora, Colorado

Predicting CD19Neg relapse following CAR T-cell therapy in B-cell precursor acute lymphoblastic leukemia*
Pablo Domizi, Stanford University School of Medicine, Stanford, California

Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers*
Harpreet Singh (presenting on behalf of Apostolia Tsimberidou), Immatics US, Inc., Houston, Texas

10-10:30 a.m.

Plenary Session 6: Optimization of Target Antigens for TCR and TIL
Session Chair: Alex Franzusoff, PACT Pharma, Inc., South San Francisco, California

10:30 a.m.-12:15 p.m.

Novel naturally presented targets for personalized T-cell therapies
Harpreet Singh, Immatics US, Inc., Houston, Texas

Personalized neoantigen-targeting adoptive TCR-T cell therapies for solid tumors
Alex Franzusoff

Personalized gene editing of T cells to express neoantigen-specific TCRs isolated from peripheral blood of patients on PD-1 blockade therapy*
Cristina Puig-Saus, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

Finding CAR-T drivers for GBM: Building a translational discovery pipeline*
Sheila Kumari Singh, McMaster University Medical Center, Hamilton, Ontario, Canada

Immunopeptidomics and peptide expression profiles to develop T-cell receptors against glioma-associated antigens*
Diego A. Carrera, University of California San Francisco School of Medicine, San Francisco, California

Lunch on Own
12:15-2:30 p.m.

Plenary Session 7: Combination Therapy with Adoptive Cell Therapy
Session Chair: Ivan M. Borrello, Johns Hopkins University, Baltimore, Maryland

2:30-4:30 p.m.

Unveiling mechanisms of response and resistance to instruct next generation cancer immunotherapy
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, Washington

Marrow-infiltrating lymphocytes: Biology and practice
Ivan M. Borrello

Combining checkpoint blockade with CAR T cell therapy to augment response
Shannon L. Maude, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Conditioning treatment with a CD27 antibody enhances in vivo expansion and antitumor activity of adoptively transferred T cells*
Li-Zhen He, Celldex Therapeutics, Inc., Hampton, New Jersey

IL-2 limits CAR T-cell efficacy through selective expansion of a differentiated and less functional subset marked by the loss of CD27 expression*
Dongrui Wang, City of Hope, Duarte, California

Poster Session B / Reception
4:30-6:30 p.m.

Top of page

Monday, July 22

Continental Breakfast
7-8 a.m.

Plenary Session 8: Enhancing Immune Cell Function through Genetic Engineering
Session Chair: Rodabe N. Amaria, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-10 a.m.

Tumor infiltrating lymphocyte therapy for metastatic melanoma
Rodabe N. Amaria

Enhancing CAR T cell therapy by enabling CAR T cell interaction with antigen-presenting cells
Clare Y. Slaney, Peter MacCallum Cancer Center, Melbourne, Australia

Strategies to improve CAR T persistence and solid tumor targeting
Avery D. Posey, Jr., University of Pennsylvania, Philadelphia, Pennsylvania

Convertible CAR-T cells provide a highly modular universal system for dose control of activity, targeting flexibility, and in vivo CAR maintenance*
Kaman Kim, Xyphos Biosciences, San Francisco, California

Adapter CAR T cells (AdCAR-T) allow precise control on effector function, prevent antigen evasion, and enable differential target cell lysis, based on complex antigen expression profiles*
Christian M. Seitz, University Children's Hospital Tübingen, Tübingen, Germany

10-10:30 a.m.

Plenary Session 9: Novel Approaches for Gene Delivery (Engineered Vectors and Viral Delivery Systems)
Session Chair: Laurence J.N. Cooper, Ziopharm Oncology, Boston, Massachusetts

10:30 a.m.-12 p.m.

T cells genetically modified using non-viral gene transfer to target cancer
Laurence J.N. Cooper

Reprogramming human immune cell circuitry
Alexander Marson, University of California San Francisco, San Francisco, California

Engineering smarter and stronger T cells for cancer immunotherapy
Yvonne Y. Chen, University of California Los Angeles, Los Angeles, California

Closing Remarks
12 p.m.

*Short talk from proffered abstract

Top of page